Detalhe da pesquisa
1.
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
N Engl J Med
; 374(1): 54-61, 2016 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26698910
2.
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Proc Natl Acad Sci U S A
; 112(11): 3493-8, 2015 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25733882
3.
Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
Drug Metab Dispos
; 43(1): 54-62, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25349124
4.
Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
J Pharmacol Exp Ther
; 351(1): 67-76, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25073473
5.
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.
Clin Cancer Res
; 30(10): 2039-2047, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231047
6.
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.
Proc Natl Acad Sci U S A
; 107(20): 9446-51, 2010 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-20439741
7.
Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
Bioorg Med Chem Lett
; 18(23): 6273-8, 2008 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18929486
8.
Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).
Sci Rep
; 7(1): 7305, 2017 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28779088
9.
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
J Hematol Oncol
; 10(1): 112, 2017 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-28526063
10.
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.
Blood Adv
; 1(15): 1088-1100, 2017 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296751
11.
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
Cancer Discov
; 6(1): 96-107, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26554404
12.
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
J Med Chem
; 59(5): 2005-24, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26756222
13.
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Cancer Cell
; 28(1): 70-81, 2015 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26144315
14.
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Clin Cancer Res
; 20(3): 631-43, 2014 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24240111
15.
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
J Med Chem
; 57(11): 4720-44, 2014 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24819116
16.
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
J Med Chem
; 57(4): 1170-87, 2014 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24432909
17.
Retraction notice to "A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells".
Cancer Lett
; 422: 132, 2018 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29579439
18.
Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
Pigment Cell Melanoma Res
; 25(6): 819-31, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22883054
19.
Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells.
PLoS One
; 7(10): e48402, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23119004
20.
Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
Clin Cancer Res
; 18(18): 5008-19, 2012 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22806875